Revvity (RVTY) closed at $152.59 on Oct 16, 2026, down 1.4% on the day. The stock is up 4.0% over the past month, up 43.4% over three months, up 57.9% year to date and up 66.0% over the past year. It trades 8.2% below its 52-week high of $166.25 and 87.9% above its 52-week low of $81.22. The close sits above its 50-day moving average ($136.12) and above its 200-day moving average ($109.08).
NextPick tracks RVTY in its Life Sciences Tools basket alongside TMO, DHR, A, WAT and MTD. As of Oct 16, 2026, the basket's money-flow score is 7 (neutral), and the basket is up 1.2% over five sessions. Over the past month RVTY ranks 6th of 10 basket members by price change.
Form 4 filings over the last 90 days show no open-market purchases and 4 open-market sales by insiders.
Yes — the Oct 16, 2026 close of $152.59 is 39.9% above the 200-day average of $109.08.
RVTY closed 8.2% below its 52-week high of $166.25.
NextPick groups RVTY with TMO, DHR, A, WAT and MTD in its Life Sciences Tools basket.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
